The limitations of our study might be represented by the relatively small cohort of CLL patients, as well as the lack of data on the plasma levels of TNF-α and IL-10 in the patient samples and the lack of finance for comprehensive genetic analyses such as whole-exome/whole-genome analysis. The gene discussed is TNF; the disease is B-cell chronic lymphocytic leukemia.